Followers | 43 |
Posts | 5751 |
Boards Moderated | 0 |
Alias Born | 04/12/2021 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, November 07, 2022 7:54:10 PM
“Second Quarter 2022 Financial Results
Total revenue was $18.8 million for the quarter ended June 30, 2022, compared with $31.0 million for the second quarter of 2021, driven by lower instrument and COVID-19 testing revenue. Base product and service revenue (excluding COVID-19 testing revenue) was $17.5 million, approximately 35% lower compared with $26.9 million for the second quarter of 2021.
GAAP net loss for the quarter ended June 30, 2022, was $63.5 million, compared with a GAAP net loss of $17.1 million for the second quarter of 2021. The year-over-year increase in GAAP net loss was driven by increases in fair value of the forward sale contract related to the Series B Preferred Stock and bridge loans aggregating $25.4 million, lower revenue, lower product and service margin, and higher operating expenses. Product line exits during the quarter negatively affected product and service gross profit and net loss by $4.7 million and $8.2 million, respectively.
Non-GAAP net loss, which excludes the fair value increases noted above, stock-based compensation, depreciation and amortization expenses, and interest expense, was $25.8 million for the quarter, compared with a non-GAAP net loss of $9.3 million for the second quarter of 2021.
Cash, cash equivalents and short-term investments as of June 30, 2022, were $211.2 million, compared with $30.0 million as of March 31, 2022.”
my posts are always theory and not financial advice
Recent LAB News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 06/03/2024 09:20:43 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/03/2024 09:19:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 10:05:51 AM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/29/2024 08:34:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 12:45:58 AM
- Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers • GlobeNewswire Inc. • 05/28/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 11:53:19 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/22/2024 08:54:28 PM
- Standard BioTools to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/22/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:37:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:35:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:34:52 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/21/2024 09:16:29 PM
- Form DEFC14A - Definitive proxy statement, contested solicitations • Edgar (US Regulatory) • 05/21/2024 09:15:29 PM
- Standard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/20/2024 12:00:00 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 05/20/2024 10:03:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 12:11:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 01:07:06 AM
- Form PREC14A - Preliminary proxy statements, contested solicitations • Edgar (US Regulatory) • 05/10/2024 09:16:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:53:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:31:44 PM
- Standard BioTools Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/08/2024 08:01:00 PM
- Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth • GlobeNewswire Inc. • 04/25/2024 12:01:00 PM
- Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM